You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 8,414,922

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,414,922 protect, and when does it expire?

Patent 8,414,922 protects KYNMOBI and is included in one NDA.

This patent has thirty-five patent family members in twenty countries.

Summary for Patent: 8,414,922

Patent landscape, scope, and claims:

Title:	Sublingual films
Abstract:	The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.
Inventor(s):	Bryson; Nathan John (Toronto, CA), Giovinazzo; Anthony John (Oakville, CA), Barnhart; Scott David (York, PA), Koons; Michael Clinton (York, PA)
Assignee:	Cynapsus Therapeutics, Inc. (Toronto, CA) ARx, LLC (Glen Rock, PA)
Application Number:	13/445,656
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound; Dosage form;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 8,414,922

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-001	May 21, 2020		DISCN	Yes	No	⤷ Subscribe	⤷ Subscribe	Y			TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE	⤷ Subscribe
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-002	May 21, 2020		DISCN	Yes	No	⤷ Subscribe	⤷ Subscribe	Y			TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE	⤷ Subscribe
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-003	May 21, 2020		DISCN	Yes	No	⤷ Subscribe	⤷ Subscribe	Y			TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE	⤷ Subscribe
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-004	May 21, 2020		DISCN	Yes	No	⤷ Subscribe	⤷ Subscribe	Y			TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,414,922

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011343429	⤷ Subscribe
Australia	2017200331	⤷ Subscribe
Australia	2019200138	⤷ Subscribe
Brazil	112013015204	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.